Shire’s Veyvondi approved in Europe for bleeding disorder
European regulators have approved Shire’s von Willebrand Disease therapy Veyvondi.
Read More
Tag: von Willebrand Disease
EU regulators reviewing Shire’s bleeding disorder drug
European regulators have validated the marketing authorisation application for Shire’s experimental von Willebrand Disease therapy Veyvondi.
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
